Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013


5,304  Interest receivable327363  Amounts receivable714449  Prepaid and other current assets3,7551,210  Property, equipment and other assets1,523689Total assets$
82,016$
8,015Liabilities and stockholders' equity:  Accounts payable and accrued liabilities$
7,050$
3,217  Deferred collaboration revenue-18,271  Current portion of long-term obligations1,0841,417  Warrant liability3,4227,881  Long term liabilities4,2536,339  Stockholders' equity66,20730,890Total liabilities and stockholders' equity$
82,016$
8,015 

Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, March 7, 2013, to provide a business update and discuss the fourth quarter and year end 2012 results.

A live event will be available on the Investor Relations section of the OncoGenex Web site at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresecta
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  BioDelivery Sciences International, Inc. (NASDAQ: ... and Chief Executive Officer of BDSI, will present at two important ... Conference Tuesday, June 2 8:30 AM Eastern Time Grand Hyatt, ... William Blair 35 th Annual Growth Stock Conference Tuesday, ... Seasons Hotel, Chicago, IL , ...
(Date:5/27/2015)... Biomedical Catalyst Award to ... Cancer  Crescendo Biologics Limited (Crescendo) today ... (ADC) programme with the support of a Biomedical ... UK. This feasibility award will enable the validation ... novel product format based on Crescendo,s Humabody™ antibody ...
(Date:5/26/2015)... 2015  AbbVie (NYSE: ABBV ) presented ... of its investigational, all-oral, interferon (IFN)- and ribavirin ... the Annual Meeting of the Japan Society of ... 1 GIFT-I evaluated genotype 1b (GT1b) chronic ... and without cirrhosis, who were either treatment-naïve or ...
Breaking Medicine Technology:BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference and the William Blair Growth Stock Conference 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference and the William Blair Growth Stock Conference 3Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6
... Stryker Corporation (NYSE: SYK ) today announced that the U.S. ... undertaken to address issues raised in two Warning Letters received in 2007 ... , , ... certain quality system requirements at its reconstructive implant manufacturing facility in ...
... China , May 19 /PRNewswire-Asia-FirstCall/ -- ... the "Company"),(OTC Bulletin Board: CRUI), a manufacturer and distributor ... pharmaceuticals, construction materials,PVC products, foods and beverages and cosmetics, ... March 31, 2010 . , , ...
Cached Medicine Technology:Stryker Announces Resolution of Two FDA Warning Letters 2China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 2China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 3China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 4China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 5China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 6China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 7China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 8China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 9China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 10China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 11China Ruitai International Holdings Co., Ltd. Reports Results for the First Quarter 2010 12
(Date:5/27/2015)... Danish scientists have published an analysis of ... potential to help in diagnosis or treatment planning for ... that has just been posted on Surviving Mesothelioma. ... new biomarkers found in blood, serum, and lung fluid ... malignant mesothelioma . , Study author Vasiliki Panou ...
(Date:5/27/2015)... 2015 The Society for Women's ... thought leader in research on sex differences in health ... campaign uniting survivors, advocates, organizations, and celebrities in bringing ... disease. The campaign features a short film that ... with chronic disease as a result of their abuse, ...
(Date:5/27/2015)... National Healthcare Providers (NHCP), ... web development and interactive marketing agency, Bayshore ... of its newly redesigned, custom website, found ... Providers, is a physician owned and operated ... of Radiology, Anesthesiology, Emergency and Hospital Medicine. ...
(Date:5/27/2015)... MD (PRWEB) May 27, 2015 ... USA, helped its client to launch an Android version ... allows merchants to accept credit, debit and ACH payments ... from Google Play at: https://play.google.com/store/apps/details?id=com.simpalm.paymentgateway . The iOS ... and has been recently updated by SIMpalm. , ...
(Date:5/27/2015)... This year, Mental Health America (MHA) is ... affected to seek assistance before a crisis occurs. According to ... five children, ages 13 to 18, are living with or ... of mental illness within one's lifetime will begin by age ... help before reaching a critical stage — particularly for young ...
Breaking Medicine News(10 mins):Health News:New Report Highlights Current and Emerging Biomarkers for Mesothelioma, According to Surviving Mesothelioma 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 2Health News:The Society for Women’s Health Research Announces “Beyond the Bruises” Campaign Highlighting the Effects of Domestic Violence on Chronic Disease 3Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Forte Payment System Launches Android Version of Payment App 2Health News:The Glenholme School Observes Mental Health Awareness Month 2Health News:The Glenholme School Observes Mental Health Awareness Month 3
... June 2010: Smoking cigarettes is a significant risk factor ... negative impact on the effectiveness of anti-tumour necrosis factor ... to results of two studies presented today at EULAR ... Rheumatism in Rome, Italy. A further study has shown ...
... ... CA will be an exciting event for Tosoh Bioscience (Booth #7714) as the company plans to ... and HPLC testing. , ... 2010 -- The AACC 2010 Annual Meeting in Anaheim, CA will be an exciting ...
... ... National Society of Certified Healthcare Business Consultants to Focus on Shared Goals of EHR ... ... of the integrated, single-database electronic health record (EHR), practice management and interoperability solution PrimeSuite®, ...
... after new rules took effect, study finds , THURSDAY, ... to doctors who administer outpatient chemotherapy drugs actually led ... finds a new study. , "This sort of dynamic ... economists often encounter this sort of thing," Joseph Newhouse, ...
... , ... Nutrition, LLC, an innovative, technology-enhanced, nutrition company, announced today that it is expanding their ... newest member to join this highly-respected team of doctors and scientists. , ... (PRWEB) June 17, 2010 ...
... , ... Themedicalsupplydepot.com, a rapidly growing online medical supplies superstore, announces a ... supplies provider—from super lightweight wheelchairs to diabetic test supplies—can be purchased easily ... ...
Cached Medicine News:Health News:Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFs 2Health News:Smoking cigarettes is a predictor of RA and may negatively impact on efficacy of anti-TNFs 3Health News:AACC 2010 Creates Excitement for Tosoh Immunoassay and HPLC Analyzers 2Health News:Greenway Partners with National Healthcare Consultancy 2Health News:Greenway Partners with National Healthcare Consultancy 3Health News:Medicare Cuts May Have Led Docs to Prescribe More Chemo 2Health News:Discount Medical Supplies Provider Now Offering International Checkout 2
Titanium. Straight shafts with 6 mm platform and Pierse tips. Flat serrated handle with dull finish....
0.12 mm, 1 x 2 teeth set at 45 degrees with 5 mm tying platform. Serrated handle with polished finish....
Serrated handle with 7 mm tying platform and polished finish. Teeth: 0.25 mm, 2 x 2 set at 45 degrees....
5 mm tying platform, serrated cross action handle with polished finish. Teeth: 0.10 mm, 1 x 2 set at 45 degrees....
Medicine Products: